Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease

✍ Scribed by Uli C. Broedl; Veronika Schachinger; Arno Lingenhel; Michael Lehrke; Renee Stark; Frank Seibold; Burkhard Göke; Florian Kronenberg; Klaus G. Parhofer; Astrid Konrad-Zerna

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 92 KB
• Volume: 13
• Category: Article
• ISSN: 1078-0998
• DOI: 10.1002/ibd.20078

✦ Synopsis

Background:

Apoa-iv, an apolipoprotein (apo) with antioxidant, antiatherogenic, and antiinflammatory properties, was recently demonstrated to inhibit dextran sulfate sodium (dss)-induced experimental colitis in mice. we therefore hypothesized that apoa-iv may be associated with disease activity in patients with inflammatory bowel disease (ibd).

Methods:

We addressed this question by testing for associations between apoa-iv genotypes, apoa-iv plasma levels, inflammatory parameters, and clinical disease activity in 206 patients with crohn's disease (cd), 95 subjects with ulcerative colitis (uc), and 157 healthy controls.

Results:

In cd patients, apoa-iv plasma levels were inversely associated with c-reactive protein (crp) (p = 0.005) and disease activity (p = 0.01) in univariate analysis. in multiple logistic regression analysis, apoa-iv levels were identified as an independent predictor of elevated crp (odds ratio [or] 0.956, 95% confidence interval [ci]: 0.916-0.998, p = 0.04) and active disease (or 0.957, 95% ci: 0.918-0.998, p = 0.04). in uc patients the apoa-iv gene variant 360 his (p = 0.03) but not apoa-iv levels (p = 0.15) were associated with increased disease activity in univariate analysis. this association, however, was lost in multiple logistic regression analysis (or 3.435, 95% ci 0.995-11.853, p = 0.05).

Conclusions:

To our knowledge, this is the first study to demonstrate an association of apoa-iv with disease activity in patients with cd. further studies are needed to define the relationship of apoa-iv to ibd.